Agios Q2 revenue jumps on US commercial launch of AQVESME

Overview

• U.S. rare disease drugmaker's Q2 product revenue rose sharply

• Net loss for Q2 narrowed year-over-year

• Growth driven by U.S. AQVESME launch and European approval of PYRUKYND

Outlook

• Agios expects to advance cevidoplenib into Phase 3 for ITP in H1 2028

• Company plans to start Phase 2/3 development of AG-236 for polycythemia vera in H2 2026

• Agios expects current cash and revenue to fund launches and pipeline advancement

Result Drivers

• U.S. LAUNCH OF AQVESME - Revenue growth was driven by the U.S. commercial launch of AQVESME (mitapivat) in thalassemia

• EUROPEAN APPROVAL - Ex-U.S. revenue reflected demand for PYRUKYND (mitapivat) in Europe after approval for thalassemia

• HIGHER OPERATING EXPENSES - RD and SGA expenses increased due to licensing costs and commercial launch activities

Company press release: ID:nGNX1BYxFd

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology medical research peer group is "buy"

• Wall Street's median 12-month price target for Agios Pharmaceuticals Inc is $46.00, about 31.4% above its July 29 closing price of $35.01

Reuters Recommended Reads

• July 28 - Italy's Recordati H1 revenue rises 6.6% on rare diseases segment growth

• July 29 - Biogen beats quarterly estimates as newer drugs drive growth

• July 28 - Kiniksa Pharmaceuticals Q2 product revenue rises on ARCALYST sales

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)